Wilex improves result


Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight.
The 2011 total revenue was better than last year (€11.7m, 2010: €1.3m), with the licence agreement from Prometheus Inc. about a therapeutic antibody named Rencarex accounting for the biggest share: In April 2011, Wilex received €19m from the Californian company which in turn, secured the rights to promote the anti-cancer remedy in the US. After an FDA approval last autumn, Rencarex is now on an amended study protocol. If data are positive, Wilex could file for drug approval in Europe and the US in early 2013. As foreseen in the Prometheus deal, the Munich biotech start-up becomes eligible for a €20m payment at the end of April. Whether Wilex grabs the money or instead takes hold of the option to secure the marketing rights in Europe for one–yet unnamed–Prometheus product remains elusive so far.
Data on Wilex' second pipeline drug Mesupron is also nervously anticipated. In a clinical Phase II study, it is being tested on 132 patients with a certain type of breast cancer. The primary endpoint PFS will be accomplished in 2012, data for overall survival will likely be available in 2013. CFO Peter Llewellyn-Davies pointed out that Wilex had diversified its service portfolio: "In 2011 we successfully integrated two acquisitions." One of them, Heidelberg Pharma, is specialised in customer-oriented CR. The other, Oncogene Science successor Wiley Inc., does in vitro diagnostic tests. For 2012 sales are expected to grow from €11.7m up to €16m. However, the operating loss would still remain between €10m and €14m (2011:€13,4m). WestLB research analyst Mark Belsey reports that due to higher revenues and lower operating costs the FY-11 results were slightly better than he expected. For FY-12 his opinion is in line with the company's expectations: His sales forecast lies at €15.6m, EBIT guidance at €-12,7m.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...



Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • SYNGENTA430.80 CHF32.0%
  • EVOLVA1.84 CHF20.3%
  • BASILEA132.00 CHF16.7%


  • CYTOS0.66 CHF-32.7%
  • MEDIGENE8.43 EUR-19.3%
  • 4SC4.65 EUR-10.6%


  • WILEX3.95 EUR393.7%
  • FORMYCON28.39 EUR318.7%
  • 4SC4.65 EUR307.9%


  • MOLOGEN5.05 EUR-52.5%
  • PAION2.54 EUR-26.8%
  • BIOFRONTERA2.29 EUR-25.6%

No liability assumed, Date: 28.05.2015

Current issue

All issues